Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab

Amr El-Husseini, Schot Hannan, Ahmed Awad, Stuart Jennings, Virgilius Cornea, B. Peter Sawaya

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


Thrombotic microangiopathy (TMA) is a severe disorder with poor outcomes. The cause is unknown for many patients, although TMA is associated with connective tissue disorders, including systemic lupus erythematosus (SLE). While uncommon, TMA is one of the most serious complications of SLE and in many cases may be resistant to therapy. We report a patient with SLE complicated by TMA that was refractory to standard therapy but responded well to eculizumab, with continued remission after 1 year of follow-up. Eculizumab might be useful in the management of resistant cases of TMA caused by SLE.

Original languageEnglish
Pages (from-to)127-130
Number of pages4
JournalAmerican Journal of Kidney Diseases
Issue number1
StatePublished - Jan 2015

Bibliographical note

Publisher Copyright:
© 2014 by the National Kidney Foundation, Inc.


  • Acute kidney injury (AKI)
  • Atypical hemolytic uremic syndrome (aHUS)
  • Eculizumab
  • Kidney biopsy
  • Lupus nephritis
  • Proteinuria
  • Systemic lupus erythematosus (SLE)
  • Thrombotic microangiopathy (TMA)

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Thrombotic microangiopathy in systemic lupus erythematosus: Efficacy of eculizumab'. Together they form a unique fingerprint.

Cite this